Elinzanetant

Papers on elinzanetant

42 papers9 new in 30 days

Wednesday, November 18

Tuesday, November 17

Monday, November 9

Thursday, November 5

Sunday, November 1

Friday, October 30

Sunday, October 25

EClinicalMedicine

Elinzanetant’s safety profile appeared favorable in women

Over 12 weeks, new or worsening health problems occurred in 50.8% of women taking elinzanetant and 43.2% taking placebo.Over 12 weeks, new or worsening health problems occurred in 50.8% of women taking elinzanetant and 43.2% taking placebo.

Study design. aFor SWITCH-1, elinzanetant 40 mg, 80 mg, and 160 mg were excluded from the pooled safety analysis.
Meta-analysis · 1,519 peopleElinzanetant

Sunday, October 18

Wednesday, October 14

Tuesday, October 6

Saturday, September 5

Tuesday, September 1

Saturday, August 1

Tuesday, July 28

Tuesday, July 14

Thursday, May 21

Friday, May 8

Tuesday, April 28

Thursday, April 23

Tuesday, March 24

Monday, March 23

Wednesday, March 18

Monday, March 16

Tuesday, February 24

Saturday, February 14